Plus Therapeutics Inc (PSTV) Stock Forecast & Price Target
Plus Therapeutics Inc · NASDAQ
$3.84-0.02 (-0.57%)
15-min delayed · Aug 7, 8:00 AM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Plus Therapeutics Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $1.00 to $57.00 (about 57.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $20.33 sits 430% above the current $3.84. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.86 next quarter toward $-2.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Plus Therapeutics Inc.
As of Aug, 2 of 3 firms rate PSTV a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PSTV EPS & revenue forecast
EPS · NEXT QUARTER
$-0.86
Range $-0.92 – $-0.80 · 3 analysts · -14% YoY
Next period, 3 analysts expect Plus Therapeutics Inc to earn $-0.86 a share (range $-0.92 – $-0.80), versus $-1.00 a year earlier. Full-year consensus is $-3.92, growing to $-2.40 the year after.
REVENUE · NEXT QUARTER
$1.5M
Range $1.0M – $2.0M · 3 analysts · +5% YoY
Revenue is expected to reach $1.5M (range $1.0M – $2.0M), +4.9% year-over-year. Full-year consensus is $6.3M, rising to $19.1M next year.
Top analysts covering Plus Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PSTV.
#1
Sean Lee
HC Wainwright & Co. · Rank #222
Buy
$1.00-73.9% to target
Overall win rate
44%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #407
Hold
No targeton PSTV
Overall win rate
22%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #417
Buy
$3.00-21.8% to target
Overall win rate
33%
+ Follow
#4
Edward Woo
Ascendiant Capital · Rank #419
Buy
$57.00+1385.1% to target
Overall win rate
25%
+ Follow
#5
SL
Sean Lee CFA
H.C. Wainwright
Buy
$25.00+551.4% to target
Coverage
—
+ Follow
PSTV stock forecast FAQ
What is PSTV's average 12-month price target?+
The 2 analysts with a live target average $20.33 for Plus Therapeutics Inc over the next 12 months, ranging from a $57.00 high to a $1.00 low.
Is PSTV stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PSTV?+
The Street-high target is $57.00 (Ascendiant Capital), and the Street-low is $1.00 (HC Wainwright & Co.). The average of all 2 active targets is $20.33.
How many Wall Street analysts cover PSTV?+
3 analysts have an active rating on Plus Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering PSTV?+
Among analysts who currently cover PSTV, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #222). Their current call is Buy with a $1.00 target.
What is Plus Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.86 per share (range $-0.92 – $-0.80) across 3 analysts. Full-year EPS is projected at $-3.92, rising to $-2.40 the following year.
How much revenue is Plus Therapeutics Inc expected to report next quarter?+
Consensus revenue is $1.5M (range $1.0M – $2.0M). Full-year revenue is projected at $6.3M, growing to $19.1M next year.
Have analysts been upgrading or downgrading PSTV lately?+
As of Aug, 2 of 3 firms rate PSTV a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PSTV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
